Can a new pill stop heartburn in its tracks?
NCT ID NCT07752407
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial tests whether vonoprazan, taken as needed, can quickly relieve heartburn episodes in adults with non-erosive gastroesophageal reflux disease (GERD). Participants will take either vonoprazan or a placebo when they experience heartburn, and researchers will track how well symptoms improve within hours and over 12 weeks. The goal is to see if this approach offers fast, sustained relief for people who have heartburn without visible damage to the esophagus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vonoprazan
- What this could lead to
- If successful, this could offer a new on-demand option for people with non-erosive GERD to quickly relieve heartburn episodes without needing daily medication.
- What could go wrong
- This is a phase 3 trial, but results are not guaranteed. The benefit over placebo may be modest, and potential side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.